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ABSTRACT 
Background: Thrombophilia is a pathological state of increased blood coagulability. It causes problems during 
pregnancy including preeclampsia, stillbirth, repeated abortions, and detached pair. Out of the most prevalent 
factors causing inherited thrombophilia, protein S (Prs), protein C (Prc), and antithrombin III (ATIII) 
deficiency, and Factor V Leiden (FVL) mutation could be mentioned. This study aimed to investigate 
association of these parameters with preeclampsia. 
Methods: In this case-control study, 142 pregnant women with preeclampsia referred to Obstetric Clinic of 
Hajar Hospital, southwest of Iran, were assigned to the case group after clinical laboratory tests and according 
to specialist point of view and 142 pregnant women with normal blood pressure were assigned to the control 
group. After obtaining consent and completing relevant questionnaire, a 4-cc blood sample was taken from 
the patients. Coagulation factors and FVL rate were measured and after 6 months patients were followed- up. 
Data analysis was done by SPSS software using t-test. 
Results: In view of deficiency of Prs, Prc, and ATIII, no statistically significant association was observed 
between case and control groups (P>0.05). Statistical t-test indicated that the rate of FVL deficiency in 
pregnant patients with preeclampsia was significantly different from that in the control group (p=0.03). In 
addition, the body mass index of case group was significantly higher than that of control group prior to 
pregnancy (P=0.001). In case group, preeclampsia history contributed to development of current 
preeclampsia in contrast to control group (p<0.001). The patients of case group were followed up after 6 
months in view of blood pressure and all had a normal mean blood pressure at the completion of the study. 
Conclusion: Measurement of FVL deficiency could help to decrease the unpleasant complications of vascular 
disorders during pregnancy. But, screening test for pre-eclampsia does not seem necessary to determine the 
deficiency of coagulation factors, Prs, Prc, and ATIII. 
 




   Thrombophilia is the increase in blood 
coagulability, which could be inherited or acquired. 
Inherited thrombophilia is a genetic predisposition, 
which was described by Egberg in 1965 for the first 
time.1 During pregnancy, the predisposition to 
inherited thrombophilia increases because the 
changes associated with pregnancy in some 
coagulation factors cause increase in resistance to 
activated protein C (Prc) during second and third 
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trimesters and decrease in activity of protein S (Prs) 
because of estrogen effects; also, factors 2, 7, 8, 9, 
and 10 increase. All these lead to increase in 
coagulability in healthy women. Therefore, an 
individual with inherited thrombophilia is at high 
risk of thromboembolic problems during pregnancy, 
which is often followed by repeated abortions, 
preeclampsia, stillbirth, intrauterine growth 
restriction (IUGR), detached pair, increase in 
cardiovascular events, deep vein thrombosis (DVT) 
and pulmonary embolism.2,3 
   Awareness of these genetic disorders (genetic 
thrombophiliae) contributes greatly to determining 
the need for antithrombotic factors for prophylaxis 
in special conditions and the risk during pregnancy. 
The majority of these disorders are developed by 
genetic mutations, causing deficiency of an 
anticoagulation factor or increase in a 
precoagulation factor.1  
   Out of the most prevalent factors causing genetic 
thrombophilia, Prs deficiency, Prc deficiency, factor 
V Leiden (FVL) mutation, and antithrombin III (ATIII) 
deficiency could be mentioned.4 In several studies 
in Turkey,5 Canada,6 Italy7 and in a study by 
Lockwood and Wendel,2 inherited thrombophilia 
was identified as a risk factor for pregnancy 
complications such as repeated abortions and 
preeclampsia. 
   Prs is a glycoprotein associated with vitamin K and 
Prc system cofactor, which is developed by 
hepatocytes and megakaryocites. Prs deficiency was 
described for the first time in 1984 and found to be 
transmitted in the form of a predominant etozome. 
Its familial prevalence has been reported 3-13%. 
This anticoagulation substance is activated by Prc in 
circulation and decreases thrombin production.2 
   Prc is a type of coagulation glycoprotein. When 
thrombin is linked to thrombomodulin in 
microvascular endothelial cells, its precoaugulation 
activities are neutralized. More than 160 mutations 
have been described for Prc with the prevalence of 
2-3 per 1000. For estimating the prevalence rate of 
Prc deficiency, the threshold level of functional 
activity of this protein is considered 50-60%.2,8 
   The most prevalent inherited disorder which leads 
to coagulation incidence is FVL mutation.4 A 
research in Australia indicated that heterozygosity 
for FVL increased the risk of intrauterine fetal 
death, detached pair and preeclampsia, but 
generally no clear association was obtained 
between inherited thrombophilia and unpleasant 
pregnancy outcome.9 
   Inability to deactivate mutated FVL allows 
prothrombin complex to remain relatively 
uninhibited, causing increase in thrombin 
production and thrombophilic phenotype.4  
   ATIII is a type of natural anticoagulation factor 
which is combined with endogenous heparin 
sulfates, inhibiting both the formed thrombin and 
the activated factor X.10 Antithrombin deficiency 
could cause resistance to heparin although in most 
cases, its deficiency does not lead to resistance to 
heparin.4 The homozygous factor deficiency is 
fatal.10 
   Prs deficiency, Prc deficiency, ATIII deficiency, and 
FVL mutation increase the risk of preeclampsia, 
repeated abortions, and intrauterine fetal death.2 
High blood pressure during pregnancy 
(preeclampsia) is hypertension accompanied with 
proteineuria after 20th week of pregnancy in the 
women with normal blood pressure prior to 
pregnancy. Preeclampsia accompanied with a 
seizure not attributable to other reasons is referred 
as eclampsia.11 Preeclampsia is diagnosed in 3.9% of 
total pregnancies and is the reason for 16% of 
maternal mortalities.11  
   Although the reason for preeclampsia is still 
unknown, some evidence is being obtained, 
suggesting that this disease is manifested during 
early pregnancy and that hidden, pathophysiologic 
changes are initiated from insemination. These are 
most probably due to vascular spasm 
consequences, disorder in endothelial function, and 
ischemia.11 Cagigrans et al. in a study in Turkey 
found that resistance to activated Prc in the women 
with preeclampsia was considerably higher and 
could be a pathogenesis for developing this disease 
during pregnancy.12 
   In a study in Romania, the association of Prc 
deficiency, Prs deficiency, and FVL deficiency with 
brain’s vascular events rate as well as with inherited 
thrombophilia was investigated, and these tests 
were found valuable for timely diagnosis of these 
events and inherited thrombophilia which may be 
developed in these individuals. But, for confirming 
this association further research is required.13 
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   In a study in Poland, polymorphism G691A of FVL 
and polymorphism G20210A of prothrombin were 
investigated and a pronounced effect of these two 
polymorphisms was found on progression of 
patients' condition toward severe preeclampsia.14 
   In Kapfremin et al.’s study in University of Delhi15 
and studies conducted in Germany16,17 and 
Canada,18 the unpleasant complications in the 
women with inherited thrombophilia decreased 
remarkably after treatment with heparin and 
aspirin. However, the definite treatment of 
preeclampsia in all cases is termination of 
pregnancy.11 
   In Chaharmahal and Bakhtiari province, 
southwestern Iran, regarding ethnographic 
characteristics of region, frequency of intrafamilial 
marriages which increases the likelihood of 
inherited diseases such as inherited thrombophilia, 
and frequency of rural population with cultural 
beliefs in these marriages and a low level of health 
care during pregnancy, research on inherited 
thrombophilia is much needed. Evidence indicates 
an association of pregnancy complications, 
including pregnancy abortions of prior to 20th week 
and afterwards, preterm deliveries, and 
preeclampsia, with inherited thrombophilia. It is 
expected that, through determining the value of 
tests measuring thrombophilia including FVL, Prc, 
Prs, and ATIII in predicting development of 
eclampsia and preeclampsia, unpleasant 
complications of pregnancy is prevented as much as 
possible. Therefore, regarding the significance of 
issue in this province, we aimed to investigate the 
association of Prc deficiency, Prs deficiency, FVL 
positivity, and ATIII deficiency in diagnosing 
pregnancy complications such as preeclampsia and 
eclampsia in comparison with healthy pregnant 
women as controls. 
 
MATERIALS AND METHODS 
   The sample population of this case-control study 
is all pregnant women admitted to Obstetric Clinic 
and Labor Unit of Hajar Hospital, southwest of Iran 
from 21 April, 2011 to 21 August, 2012. The 
development of eclampsia and preeclampsia had 
been already confirmed based on clinical 
symptoms, routine tests, and diagnosis of the 
gynecologists. The pregnant women having multiple 
pregnancies, receiving treatment (heparin, aspirin, 
and enoxaparin) during pregnancy and declining to 
participate in the study were excluded. 
   It is assumed that deficiency of coagulation factors 
is 15% in the pregnant women with pre-eclampsia 
and eclampsia and 5% in pregnant women with no 
complication. Also, the confidence interval (CI) is 
95% and test power is 80%. The study included 284 
patients assigned to two groups of 142 each (142 
pregnant women with pre-eclampsia and eclampsia 
were considered as the case group and 142 healthy 
pregnant women were considered as the control 
group). Having justified the patients, given 
explanations to the patients, obtained written 
consent, done complete physical examination, and 
obtained detailed description, we registered the 
required data in a questionnaire (including 
demographic characteristics, coagulation events, 
body mass index [BMI], smoking, the medications 
taken, history of surgery, hematological and 
rheumatoid diseases, pregnancy and abortion 
status, gestational age, and history of diseases 
during pregnancy such as pre-eclampsia, eclampsia, 
and detached pair) to measure the blood pressure 
of patients after six months of follow-up. Then, a 4-
cc blood sample was taken from the patients and 
then was tested for the rate of ATIII, Prs, Prc and 
FVL in laboratory within half an hour. 
   FVL level was measured per coagulant assay 
(Hyphen Biomed, France). FVL measurement was 
done on two PTT tests obtained from patient. In 
one of the tests, activated Prc was added to the 
sample containing patients’ plasma and then the 
relative time of thromboplastin was assessed. In 
patients with FVL mutation, Prc introduction could 
not suitably extend the time of thromboplastin 
compared to normal individuals.10 If the patient has 
no FVL resistance to Prc (no FVL mutation), PTT of 
the first tube is half PTT of the second tube in the 
presence of Prc. But, if the patient is FVL positive, 
there is little difference between the two tubes. The 
patients with index of two and higher are 
considered FVL-negative and with index of less than 
two are considered FVL-positive.10 
   ATIII was measured per chromogenic assay 
(Biophen Antithrombin 2.5, France). Antithrombin 
measurement by this method is synthetic, based on 
factor XA inhibitor, which involves formation of a 
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stable, increased concentration by antithrombin in 
the presence of heparin. Normal range of ATIII 
activity is 80-120%.2 
   Prc and Prs levels were measured using ELISA 
(AESKU, Germany). Normal range of Prs activity is 
60-150% and that of Prc is 65-140%.2 After 
collecting data and conducting secondary 
examinations, we analyzed them by means of SPSS 
software using t-test. 
 
RESULTS 
   To examine deficiency of coagulation factors, Prc, 
Prs, and ATIII, and FVL positivity, the following data 
were obtained in this study. In total, 142 qualified 
pregnant women with pre-eclampsia (case group) 
and 142 healthy pregnant women (control group) 
were enrolled. The age range of patients in the case 
and control groups was 18-42 (mean: 28.8±5.7) and 
18-38 (mean: 25.8±4.8) years, respectively. 
Independent t-test indicated no difference in age 
between the two groups. No difference in 
education levels was observed between the two 
groups (P>0.05) (Table 1).  
Table 1. Occupation status in the case and control groups 
Occupation status 
Group 
Total Case Control 
Employed 
6 6 12 4.2% 4.2% 4.2% 
Housekeeper 
136 136 272 95.8% 95.8% 95.8% 
Total 142 142 284  
   In terms of education, 13 patients (46%) were 
illiterate, 51 (18%) had elementary education, 63 
(22.2%) guidance school education, 113 (39.8%) 
high school education, and 64 (15.5%) academic 
education. In terms of the number of pregnancies, 
151 patients (53.2%) experienced the first 
pregnancy, 62 (23.2%) the second, 37 (13%) the 
third, 20 (7%) the fourth, and 10 (3.5%) the fifth and 
more. In this regard, no difference was observed 
between the two groups, as well (P>0.05). 
The pre-and post-pregnancy weight, height and BMI 
are shown in Table 2. In view of thrombosis, only 
two patients in the case group had thrombosis of 
DVT type, showing no significant difference 
between the two groups. Table 3 indicates the 
history of unpleasant complications in the two 
groups. 
 
Table 2. Weight, height and BMI of the women under study 
Variable Group (Mean ± SD) Level of significance  Case Control Pre-pregnancy weight 63.6±12.3 61±11.1 0.041 Post-pregnancy weight 77.3±12.5 73.6±11.1 0.009 Height 160.7±5 161.7±6.2 0.123 Pre-pregnancy BMI 24.6±4.5 23.2±4.1 0.008 Post-pregnancy BMI 30±4.5 28.1±4 0.001 
 
Table 3. History of disease in the case and control groups 
Group/Disease 
Case Control 
P value No. % No. % Fetal loss 2 1.4 0 0 0.156 Preeclampsia history 21 14.8 1 0.7 <0.001 Abortion history 24 23 23 16.2 0.873 Thrombosis history 2 0 0 0 0.156 
 
   As Table 4 indicates, no significant difference in 
deficiency of coagulation factors (Prc, Prs, and ATIII) 
was observed between the two groups. In FVL 
deficiency, a unidirectional significance was 
observed. 
 
Table 4. The rate of deficiency of coagulation factors in pregnant women with preeclampsia in comparison with healthy pregnant women Deficiency Type Case Control Level of significance No. % No. % Prs Deficiency 2 1.4 6 4.2 0.282 Prc Deficiency 0 0 0 0 - ATIII Deficiency 0 0 0 0 - FVL Deficiency 5 3.5 0 0 0.03 *Level of significance is unidirectional (It is assumed that this is higher in the case group). 
 
DISCUSSION 
   Mean age was 26.8±5.7 years in case group, which 
is not considered an age for high risk pregnancies,2 
and it could be argued that pregnancy conditions in 
this mean age is more tolerable in view of structural 
physiology and involves fewer underlying diseases.2 
   Occupational status and educational level are 
thought to have no effect on disease development 
because in the investigations conducted, there was 
IJHOSCR, 1 October 2014. Volume 8, Number 4    Prs, Prc, AIII and FVL with preeclampsia, eclampsia 
9 
 International Journal of Hematology Oncology and Stem Cell Research 
ijhoscr.tums.ac.ir  
 
no association between occupational status and 
housekeeping as well as educational level with 
incidence rate of preeclampsia and eclampsia.  
Thirty nine participants in the case group and 45 in 
the control group had Prs deficiency. After 
statistical analysis of data, no statistical association 
was found between the case and control groups. 
   Prc deficiency was observed in 6 and 3 
participants in the case and control groups, 
respectively. No statistically association was found 
between Prc deficiency and preeclampsia and/or 
eclampsia incidence in this study. No significant 
association was observed between this deficiency 
and disease incidence. Protein decrease less than 
50% and 30%, defined as the least natural rate of 
Prc and Prs, is considered as Prc and Prs deficiency, 
respectively. Based on this definition, no Prc 
deficiency was observed in the case and control 
groups, while 2 women in the case group and 6 in 
the control group were diagnosed with Prs 
deficiency. 
  Moreover, 22 women in the case group and 33 in 
the control group showed ATIII deficiency, but there 
was no significant association between ATIII 
deficiency and disease incidence.  
   In this study, 5 women in the case group were 
diagnosed with FVL deficiency, while no healthy 
pregnant woman in the control group showed FVL 
deficiency. The association was statistically 
unidirectional (P=0.03). No significant difference 
was seen in deficiency of coagulation factors, Prs, 
Prc and ATIII between the two groups. Therefore, 
based on the results of this study, FVL 
measurement is essential to diagnose unpleasant 
pregnancy complications. Some studies have 
revealed that FVL deficiency is prevalent among 
some ethnic groups but rare in others.20 
   Similar results were obtained in studies conducted 
in Poland21 and Italy.22 FVL mutation has a direct 
and dependent relationship with unpleasant 
outcomes of pregnancy. In Klis et al.’s study, FVL 
factor mutation (except O blood type) and Prc 
deficiency were found to have the highest 
prevalence in the patients suffering from 
unpleasant pregnancy outcomes.23 In a study 
conducted in Australia, unpleasant pregnancy 
outcomes were six times higher in the patients with 
FVL mutation compared to normal population of 
the community.19 In an investigation conducted in 
London on vascular complications of the pair and its 
association with FVL, prothrombin G20210A, 
MTHFR C677T and beta fibrinogen, only FVL had a 
contribution to increase in incidence rate of pair’s 
vascular events compared to the control group,24 
which is in agreement with the result of the present 
study. FVL deficiency could have a role in eclampsia 
and/or preeclampsia incidence. Through identifying 
the patients at risk of this factor's deficiency which, 
in turn, could cause coagulation events during 
pregnancy and ecclampsia and/or preeclampsia 
exacerbation, development of pregnancy 
complications could be notably prevented by means 
of timely and efficient medical therapeutic 
interventions and even screening of pregnant 
women for FVL deficiency. In a study by Lund et al. 
in Denmark on thrombophilia and repeated 
abortions, FVL mutation and prothrombin had no 
value in predicting live birth in mothers with 
repeated abortions, but the present study indicates 
no effect of other factors on preventing pregnancy 
failures and treatment with anticoagulants 
improves pregnancy prognosis in the women with 
FVL mutation and prothrombin mutation with 
repeated pregnancy failure .25 Pabinger conducted a 
study in Vienna, Austria and expressed screening 
mothers with repeated pregnancy failures, 
thrombophilia and timely treatment with 
anticoagulants such as enoxaparin could lead to 
pleasant pregnancy outcome. A strong association 
has been found between phospholipid antibodies 
and antithrombin deficiency, FVL, prothrombin 
G20210A mutation, Prc deficiency, Prs deficiency, 
inherited thrombophilia, and by extension, positive 
culmination of pregnancy.26 
   However, different results could be due to ethnic 
differences, study criteria and the sample size in 
different studies. 
   The results of the present study demonstrated the 
effect of preeclampsia history on the incidence of 
preeclampsia in the case group compared to the 
control group (P<0.001), meaning that the risk of 
disease could be decreased by identifying patient’s 
disease history, developing a comprehensive 
training program, more detailed care during 
pregnancy and medical treatments . 
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   Treatment of venous thromboembolism patients 
in terms of FVL is similar to patients without a 
recognized thrombophilia. No long-term 
prophylaxis is needed unless the patient 
experiences thrombosis event more than once. 
Asymptomatic patients need no treatment, but the 
women with FVL mutation should be made aware 
of increased possibility of thrombosis during 
pregnancy and also of the fact that prophylaxis is 
necessary for these patients with high risk of 
thrombosis like surgery.2 Presence of thrombosis in 
preeclampsia suggests that endothelial function 
contributes greatly to pathogenesis of thrombosis 
development in pre-eclampsia.27 
   In the present study, the blood pressure of 142 
pregnant women (control group) was measured 
after six months of follow-up and their blood 
pressure was 125/85 at the completion of the 
study. It is worth mentioning that no special 
intervention except routine standard treatments for 
eclampsia and preeclampsia based on scientific 
resources was adopted in this study. In a study in 
the USA, the administration of anticoagulants such 
as heparin and enoxaparin was the first choice for 
preventing pregnancy difficulties like stillbirth, 
IUGR, preeclampsia, and detached pair as they do 
not pass pair, decrease the risk of these diseases, 
and are not tratogenic. But, warfarin was better to 
be used post delivery because of the effects which 
it exerts on fetus.28 
   In this study, prepregnancy BMI of case group was 
significantly higher than that of control group; 
preeclampsia incidence could be prevented through 
prepregnancy weight loss. 
 
CONCLUSION 
   Preeclampsia/eclampsia is one of the most 
dangerous syndromes during pregnancy, being one 
of the members of fatal triads together with 
bleeding and infection, and is the reason for 16% of 
maternal mortalities. No significant difference was 
seen in deficiency of coagulation factors, Prs, Prc 
and ATIII between pregnant women with 
preeclampsia and healthy pregnant women in the 
studied region. No clear evidence of the association 
between above-mentioned factors and unpleasant 
pregnancy complications was found, so it did not 
seem necessary to test the patients with 
preeclampsia for the rate of Prs, Prc and ATIII. 
   However, the study indicated a significant 
association between FVL deficiency and unpleasant 
pregnancy complications. FVL measurement was 
also shown to help to decrease the development of 
vascular disorders derived from FVL deficiency 
during pregnancy. Meanwhile, maternal mortalities 
could be notably reduced through appropriate 
training and formulation of interventional plans 
such as weight loss, etc. However, other 
coagulation factors, genetic traits and racial 
qualities of different populations should not be 
ignored and further research is needed to obtain 
more inclusive findings. 
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